Follow us on Twitter
twitter icon@FreshPatents


Weight Loss patents

      

This page is updated frequently with new Weight Loss-related patent applications.




 Core 22 human training and weight loss system patent thumbnailCore 22 human training and weight loss system
The system of the preferred embodiments is a method for human training coordinated by a computer interface, where a human user interacts with at least one computing interface; where the at least one computing is provided by a computing device having at least one processor, computer readable storage medium, and a network connection to at least one additional computing device; where the user can enter and read from the computing interface; where the computing device executes computer software code; where the user executes steps displayed by the computing interface related to at least what types of food and how much food the user eats; where the computing interface displays at least once a week at least seven of at least one of questions and instructions to the user related to at least one area including water consumption, types of food eaten, timing of food eaten, type of drink consumed, amount of sleep the user has gotten, dietary supplements taken, amount of food eaten, amount of specific types of foods eaten, whether or not foods eaten fall into certain categories provided to the user in association with the method, characteristics of drink consumed, exercise carried out by the user, amount consumed by the user in certain nutritional categories, food purchased, bowel movements, and resistance of urges; where the user inputs at least one of answers and responses to the at least seven of at least one of questions and instructions; where the computing interface further prompts the user to input at least one of a) the user's weight, b) the user's body fat percentage, c) the user's waist measurements, and d) the user's body mass index; where the computer interface provides the user with a comparison between the user's answers to the at least seven questions to the progress over time of at least one of a) the user's weight, b) the user's body fat percentage, c) the user's waist measurements, and d) the user's body mass index. The method for human training coordinated by a computer interface is preferably designed to help a user lose weight, providing an understanding of the factors that lead to weight loss, providing feedback to the user to give them an understanding of how the factors relate to their weight loss, allowing for social support from others to encourage the user to stay with the program, and manipulating food intake to get the hypothalamus to aide the user in losing weight.

 Oxyntomodulin analogs and methods of making and using same patent thumbnailOxyntomodulin analogs and methods of making and using same
Provided are oxyntomodulin analogs. The peptide analogs have at least two cysteines.
California Institute For Biomedical Research


 Implantable weight control device to promote early and prolonged satiety in a bariatric patient patent thumbnailImplantable weight control device to promote early and prolonged satiety in a bariatric patient
The present disclosure provides an inflatable weight control device that is implanted long-term with an endoscope in obese and bariatric human patients to promote early and prolonged satiety. The device includes a flexible member coupled to a valve body assembly and an elongated durable module residing within the flexible member.
Agt Inc.


 Heat and flame resistant polyurethane foam patent thumbnailHeat and flame resistant polyurethane foam
The present invention relates to a reactive formulation used to make a heat and flame resistant flexible polyurethane foam which is particularly suited for use in under the hood vehicle applications which require sound deadening and vibration management and a process to make said foam. Said foam is particularly suitable for such applications because desirable heat and flame resistant properties are achieved after exposure to heat over an extended period of time.
Dow Global Technologies Llc


 Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache, and pain control, asthma, angina, hypertension, depression, cold, flue and the like patent thumbnailBiosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache, and pain control, asthma, angina, hypertension, depression, cold, flue and the like
Systems and methods for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and treating hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, attention deficit disorder and nicotine addiction involve synchronizing and tailoring the administration of nutraceuticals, medications and other substances in accordance with the body's natural circadian rhythms, meal times and other factors. Improved control of blood glucose levels, extended alertness, and weight control, and counteracting of disease symptoms when they are at their worst are possible.

 Compositions and methods for increasing the suppression of hunger and reducing the digestibility of non-fat energy satiety patent thumbnailCompositions and methods for increasing the suppression of hunger and reducing the digestibility of non-fat energy satiety
The present invention relates to methods for increasing the suppression of hunger and/or increasing the reduction of prospective consumption and/or increasing the reduction of appetite and/or increasing the feeling of satiety and/or reducing non-fat energy uptake in the gastrointestinal tract of a mammal in order to prevent a positive non-fat energy balance, weight gain, overweight and obesity, and to induce a negative non-fat energy balance and weight loss in subjects who wish to reduce their body weight. In particular, feed, food and/or beverages and dietary supplements of the present invention comprises mucilage such as flax seed mucilage and/or one or more active compounds of mucilage useful for increasing the suppression of hunger and/or increasing the reduction of prospective consumption and/or increasing the reduction of appetite and/or increasing the feeling of satiety and/or reducing the digestibility of non-fat energy in the gastrointestinal tract of a mammal..
University Of Copenhagen


 Compositions comprising cinnamaldehyde and zinc and methods of using such compositions patent thumbnailCompositions comprising cinnamaldehyde and zinc and methods of using such compositions
Compositions comprise an amount of cinnamaldehyde that is orally tolerable, thus avoiding an unpleasant mouth feeling, and also tolerable in the gastrointestinal tract. The amount of cinnamaldehyde is supplemented by zinc, and the combination is effective to increase at least one of energy expenditure, sympathetic nervous system activity, or fat oxidation, relative to a composition lacking cinnamaldehyde and zinc but otherwise identical.
Nestec S.a.


 Method for manufacturing high-strength galvanized steel sheet patent thumbnailMethod for manufacturing high-strength galvanized steel sheet
A method for manufacturing a high-strength galvanized steel sheet. The method includes a first heating step of holding the steel sheet in a temperature range of 750° c.
Jfe Steel Corporation


 Small molecule compound and synthesizing method and uses thereof patent thumbnailSmall molecule compound and synthesizing method and uses thereof
Provided is a small molecule compound as represented by structural formula (i). The product of the present invention in various concentrations and dosages can achieve an obvious change in the growth period of hairs, promoting the growth of the hairs, thus exhibiting an obvious effect of promoting hair growth.
Technoderma Medicines Pte Ltd.


 Plant extract composition for reducing topical fat and promoting weight loss as well as applications thereof patent thumbnailPlant extract composition for reducing topical fat and promoting weight loss as well as applications thereof
Disclosed in the present invention is the composition for reducing local fat and body weight, and pharmaceuticals and use thereof. The composition contains resveratrol and curcumin extract at a weight ration from 1:30 to 10:1.
Caliway Biopharmaceuticals Co., Ltd.


Composition of plant extract and its pharmaceutical composition and application thereof

Provided is a plant extract composition and a pharmaceutical composition thereof for reducing body weight and body fat, wherein the plant extract composition comprises a green tea extract and a turmeric extract respectively 30 wt % to 75 wt % and 20 wt % to 55 wt % of a total weight of the composition. In diet-induced obesity models, either obesity is induced first or simultaneously with administration, the plant extract composition and a pharmaceutical composition thereof can reduce body weight and body fat more significantly than a single plant extract or commercially available weight loss drugs..
Caliway Biopharmaceuticals Co., Ltd.

Plant extract composition for reducing topical fat and promoting weight loss as well as application thereof

Provided is a composition and a pharmaceutical composition for reducing topical fat or promoting weight loss, wherein the composition comprises a plant extract composition comprising resveratrol and turmeric extract and a weight ratio of resveratrol and turmeric extract ranges from 1:30 to 10:1. The composition and the pharmaceutical composition are primarily administered through topical injection to inhibit the growth of fat cells and promote fat cells apoptosis to reduce adipocytes, decrease topical fat deposition, and promote weight loss, without causing inflammation or necrosis on peripheral cells or tissues to avoid severe pain, so as to avoid inflammation, damage, and pain caused by surgical liposuction or non-surgical lipolysis products such as phosphatidylcholine and sodium deoxycholate..
Caliway Biopharmaceuticals Co., Ltd.

Anti-depression compounds

This technology relates generally to compounds and methods for stimulating neurogenesis (e.g., post-natal neurogenesis, including post-natal hippocampal and hypothalamic neurogenesis) and/or protecting neuronal cell from cell death. Various compounds are disclosed herein.
Board Of Regents Of The University Of Texas System

Methods and devices for activating brown adipose tissue with targeted substance delivery

Methods and devices are provided for activating brown adipose tissue with targeted substance delivery. Generally, the methods and devices can activate bat to increase thermogenesis, e.g., increase heat production in the patient, which over time can lead to weight loss and/or improved metabolic function.
The General Hospital Corporation D/b/a, Massachusetts General Hospital

Methods for determining gene-nutrient interactions

The present invention provides methods and tests that allow for the establishment of personalized weight-management programs for an individual based upon the individual's genotype in the glutathione s-transferase pi gene and/or the interleukin-6 gene. Methods are disclosed for determining the individual's genotype, which may be used to select an appropriate therapeutic/dietary program or lifestyle recommendation.
Bodysync, Inc.

Nutritional supplement for the enhancement of muscle irisin and enhancement of brown fat, metabolic rate, and weight loss, and methods of use thereof

The present invention includes a method of activating irisin by administering to an individual in need of such treatment a composition comprising irisin-activating ingredients, thus increasing the conversion of white fat to bat, and consequently, increasing metabolic rate and promoting weight loss. In an embodiment, the composition includes a gynostemma pentaphyllum extract, a polygonum cuspidatum root extract, capsaicinoids, and grains of paradise or constituents thereof.
Maximum Human Performance, Llc

F10 inhibits growth of pc3 xenografts and enhances the effects of radiation therapy

Chemotherapy remains of limited use for the treatment of prostate cancer with only one drug, docetaxel, demonstrating a modest survival advantage for treatment of late-stage disease. Data from the nci 60 cell line screen indicated that the castration-resistant prostate cancer cell lines pc3 and du145 were more sensitive than average to the novel polymeric fluoropyrimidine (fp), f10, despite displaying less than average sensitivity to the widely-used fp, 5fu.
Wake Forest University

Low dose topiramate/phentermine composition and methods of use thereof

A method for effecting weight loss by administering a combination of topiramate and phentermine is provided. The phentermine is generally administered in immediate release form, in a daily dose in the range of 2 mg to 8 mg, in combination with a daily dose of topiramate selected to prevent the loss of effectiveness of phentermine alone.
Vivus, Inc.

Peptide yy (pyy) analogues

Analogues of peptide yy (pyy), which are useful in treating disorders such as diabetes and obesity and also for inducing cosmetic weight loss, related compositions, formulations, uses and methods.. .
Imperial Innovations Limited

Method and system for increasing brown adipose tissue activity during sleep

A method and system is provided for increasing brown adipose tissue deposits and activity by breathing air from a cpap machine having a chiller which cools the air to less than 55° f. Before discharge from the cpap mask to the person's lungs while sleeping.

Exercise sauna having far infrared heating elements and configurable seating

A far infrared (“fir”) sauna cabin equipped with a far infrared (“fir”) heating elements constructed of ceramic, carbon, and/or light emitting diodes (“led”), designed for therapeutic use in a sauna, capable of emitting far infrared energy, and heating an individual's skin for purposes of rejuvenation, anti-aging, weight loss, and acne therapy. The fir heating element emits ir energy in a wavelength and frequency optimum for resonant absorption by the human body, resulting in the release of toxins stored within subcutaneous fatty deposits, which are then carried out of the person's system as he or she sweats.

Hmg1 antibody for treating inflammatory conditions

There is disclosed a pharmaceutical composition and method for treating sepsis, including septic shock and ards (acute respiratory distress syndrome), comprising administering an effective amount of a hmg1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring the serum concentration of hmg1 in a patient exhibiting or at risk of exhibiting sepsis or septic shock symptoms.
The Feinstein Institute For Medical Research

Method for modifying nickel microparticles and producing nickel microparticles

Provided is a method for modifying nickel microparticles comprising a step of making an acid and/or hydrogen peroxide act on nickel microparticles weight loss of which occurs due to heat treatment such as burning and a method for producing nickel microparticles comprising the modification method. The step of making an acid and/or hydrogen peroxide act reduces a rate of weight loss due to heat treatment of the nickel microparticles, nitric acid or a mixture of acids that include nitric acid is preferably used as the acid, and the nickel microparticles and acid and/or hydrogen peroxide are preferably made to act in a ketonic solvent..

Use of ave0010 for the treatment of diabetes mellitus type 2

The present invention refers to the use of lixisenatide or/and a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of diabetes mellitus type 2, for inducing weight loss in diabetes type 2 patients or/and for preventing weight gain in diabetes type 2 patients.. .
Sanofi-aventis Deutschland Gmbh

Method of making an adjunct to potentiate blocking of ribosomal functions in tumor cells and prevent body weight loss during cyclophosphamide cancer therapy

A method of obtaining one or more fractions from a plant material of withania somnifera (ws) is disclosed. The method includes subjecting the plant material to hydro-alcoholic extraction in presence of a water-insoluble solvent to obtain at least one extract.

Methods for treating obesity and/or metabolic syndrome

The present disclosure provides methods of treating or preventing obesity or causing weight loss or treating or preventing metabolic syndrome comprising administering to a subject a population of cells enriched for stro-1+ cells and/or progeny thereof and/or soluble factors derived therefrom.. .
Mesoblast, Inc.

Combination therapy for effecting weight loss and treating obesity

The combination methods of the present invention also are effective against symptoms associated with syndrome x. The invention also features pharmaceutical compositions and kits for use in the practice of these novel therapies..

Cyclohexene derivative, preparation method therefor, and pharmaceutical composition for preventing or treating metabolic diseases, containing same as active ingredient

The present invention relates to: a cyclohexene derivative; a preparation method therefor; and a pharmaceutical composition for preventing or treating metabolic diseases, containing the same as an active ingredient. The cyclohexene derivative according to the present invention increases the intracellular activity of cyclic adenosine monophosphate (camp) by activating g protein-coupled receptor 119 (gpr-119) and simultaneously exhibits weight loss and hypoglycemic effects by inducing the release of glucagon-like peptide-1 (glp-1), which is a neuroendocrine protein, and thus can be useful as a pharmaceutical composition for preventing or treating metabolic diseases such as obesity, type 1 diabetes, type 2 diabetes, inadequate glucose tolerance, insulin resistance, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia and syndrome x..
Hyundai Pharm Co., Ltd.

Bariatric device and weight loss

A bariatric device for use in inducing weight loss, comprising a cardiac element, a pyloric element, and a connecting element between the two other elements, wherein the connecting element provides structure between the cardiac and pyloric elements, keeping them largely in place and at least intermittently touching and applying pressure to the stomach's cardiac, adjacent fundic and pyloric regions, respectively, which produces a satiety signal to the user, giving the recipient a feeling of fullness and reducing his or her hunger feelings. In an alternative embodiment, the pyloric and connecting elements may be replaced with a positioning element, which keeps the cardiac element in its relative position by pushing against various structures in the stomach.
Apollo Endosurgery, Inc.

Apparatus and methods of inducing weight loss using blood flow control

Methods and apparatus for inducing weight loss using blood flow control are described herein. The apparatus and methods operate by controlling blood flow to the stomach and/or small bowel..
Mayo Foundation For Medical Education And Research

Non-phthalic plasticiser

The present invention refers to a method for producing a low-emitting plasticised polyvinylchloride composition, having a fusion time of less than 5.50 s and a volatility of less than 10% weight loss, by mixing pentaerythritol tetravalerate with a polyvinylchloride composition, the fusion time being measured according to din 54 802 and iso/dis 4574 and the volatility being measured according to iso 176 method a. In a further aspect the present invention refers to a thermoplastic article suitable for use in environments where the article is exposed to heat, wherein the thermoplastic article is based on a plasticized polyvinylchloride composition produced by the method of the present invention..
Perstorp Ab

Glechoma longitube extract, preparation same, and use thereof in sugar reduction, weight loss, and lipid reduction

Disclosed is a glechoma longituba (nakai) kupr. Extract, specifically compounds i and ii, a preparation method for same, and a use thereof in preparing a medicament for blood glucose decease, blood lipids decrease, weight loss, and kidney disease treatment or a method for treatment of said diseases, and a composition containing the extract..
Nanjing Pailexing Pharmaceutical Technology Ltd.

Method and system for improving weight management interventions by assessing variability in serial weight measurements

The present disclosure features novel methods and systems of using a computer system to facilitate improvement of a weight management intervention. In one embodiment, a method of improving a weight management intervention comprises receiving, by an analysis agent executing on a processor, a daily weight measurement of a patient enrolled in the weight management intervention.

Oligonucleotide compositions and methods for treating acute lymphoblastic leukemia

F10 is an oligonucleotide based on the thymidylate synthase (ts) inhibitory 5-fluorouracil (5-fu) metabolite, 5-fluoro-2′-deoxyuridine-5′-o-monophosphate. The activity of f10 against preclinical all models was determined.

Dietary and nutritional compositions and methods of use

A hydrated lecithin carrier vesicle composition includes lecithin and a triglyceride source or fatty acid in conditioned water. The disclosed compositions may be used for controlling appetite, weight loss, modulating effects from alcohol consumption, and/or delivering active agents to the small intestine..
Brightside Innovations, Inc.

Devices and methods for weight control and weight loss

The present invention provides compositions, devices; and methods for affecting, among other things, weight loss and/or weight control, by sequestering nutrients or other compounds such as toxins from absorption in the digestive tract. The compositions, devices, and methods employ one or more members made of a compressible, absorbent matrix material.
Slendine Sa

Autograft reinforcement of stapled tissue

A vascularized autograft created by an autograft-forming apparatus and method, for surgical staple line reinforcement to prevent post-operative staple line leaks following a laparoscopic sleeve gastrectomy for weight loss. Staple line reinforcement includes creating and positioning a vascularized autograft simultaneous with the gastric transection and serial stapling portions of a laparoscopic sleeve gastrectomy (lsg) procedure.

Randomized weight modulation

A method of modulating an individual's weight generates a randomized daily caloric intake value based on an individual's body composition and metabolic rates and the individual's specific weight management goals, including weight loss, weight gain, or weight control and eliminates the individual's foreknowledge of future daily caloric or nutritional intake goals. Once the individual's base metabolic rate is determined, a series of categories, each having a different daily caloric intake value, is calculated to provide a range of daily caloric intake values.

Formulation of a mixture of free-b-ring flavonoids and flavans as a therapeutic agent

The present invention provides a novel composition of matter comprised of a mixture of two specific classes of compounds—free-b-ring flavonoids and flavans—for use in the prevention and treatment of diseases and conditions mediated by the cox-2 and 5-lo pathways. The present invention further provides a novel method for simultaneously inhibiting the cyclooxygenase-2 (cox-2) and 5-lipoxygenase (5-lo) enzymes, and reducing cox-2 mrna production.
Unigen, Inc.

Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders

The present invention is directed to the use of co-therapy comprising administration of canagliflozin and phentermine for the treatment of obesity and obesity related disorders. More particularly, the present invention is directed to co-therapy for treating obesity, for promoting weight loss and/or for suppressing appetite; for treating, delaying, slowing the progression of and/or preventing metabolic disorders (including for example type 2 diabetes mellitus); for treating, delaying, slowing the progression of and/or preventing renal or fatty liver disorders (including for example nash, nafld, etc.); for treating, delaying, slowing the progression of and/or preventing sleep disorders (including for example sleep apnea); for providing cardiovascular protection; for treating, delaying, slowing the progression of and/or preventing cardiovascular events (including major adverse cardiac events (mace) such as myocardial infarction, unstable angina, cardiovascular death, revascularization, fatal or non-fatal cerebrovascular accident, peripheral arteriopathy, aortic events, hospitalization due to congestive heart failure, etc.); and/or for extending or prolonging life span..
Janssen Pharmaceutica Nv

Multi-phase release of sports nutrition and energy drink compositions utilizing lipid particulates

Multi-phase release compositions, methods of using the compositions, and methods for manufacturing the compositions are provided. Multi-phase release compositions include ingredients useful in sports nutrition including ingredients useful in muscle building, energy output and weight loss.
Corr-jensen, Inc.

Scroll compressor

A scroll compressor is provided that may include a casing having a sealed inner space; a drive motor provided in the inner space of the casing to generate a rotational force; a rotational shaft rotatably coupled to the drive motor; an orbiting scroll formed of an aluminum material, and coupled to the rotational shaft to perform an orbiting movement; a fixed scroll coupled to the orbiting scroll to form a compression space; and an oldham ring coupled to the orbiting scroll, and formed of a sintered metal. With this structure, it may be possible to prevent the oldham ring from being worn out due to contact with the orbiting scroll.
Lg Electronics Inc.

Methods and compositions for increasing fertility and/or inhibiting pregnancy failure and restoring glucose tolerance

Methods and compositions for enhancing fertility and/or inhibiting pregnancy failure, restoring glucose tolerance and/or preventing glucose intolerance and/or maintaining glucose homeostasis and/or increasing insulin sensitivity and/or preventing weight gain and/or inducing or enhancing weight loss, treating dyslipidemia, treating hypertestosteronism or hyperandrogenism, and/or treating type 2 diabetes in an individual in need thereof are provided.. .
Queens University At Kingston

Method for producing high-strength galvanized steel sheet and high-strength galvannealed steel sheet (as amended)

A method is provided for producing a high-strength galvanized steel sheet having a microstructure that contains martensite in an area proportion of 20% or more and 60% or less and ferrite in an area proportion of 40% or more and 80% or less includes, in sequence, hot-rolling a steel slab containing a specific component composition, performing cold rolling, performing primary annealing, performing pickling, performing secondary annealing, and performing galvanizing treatment, in which in the primary annealing, heating is performed at an average heating rate of 0.1° c./sec. Or more and less than 3° c./sec.
Jfe Steel Corporation

Muscles and bones stretching health device

A muscles and bones stretching health device is constituted by combining the following components together: a back rest, at least one elastic element, a seat cushion, at least one support boy, vertical first, second and third support elements and a base. Whereby, a variety of fitness postures can be done through the back rest, seat cushion and support bodies so as to achieve the stretch of muscles and bones, weight loss and physical fitness, and increase use convenience..

Metap2 inhibitors and methods of treating obesity

The present invention relates to modified or polymer conjugated metap2 inhibitors. The present invention also relates to methods of preventing, inducing, causing or increasing weight loss, treating obesity and/or treating metabolic syndrome utilizing the modified or polymer conjugated metap2 inhibitors.
Syndevrx, Inc.

Method and gastrointestinal tract ablation to achieve loss of persistent and/or recurrent excess body weight following a weight loss operation

Devices and methods are provided for ablational treatment of regions of the digestive tract in post-bariatric surgery patients who fail to achieve or maintain the desired weight loss. Bariatric procedures include roux-en-y gastric bypass, biliopancreatic diversion, and sleeve gastrectomy.
Covidien Lp

Compositions for affecting weight loss

Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (mc3-r) or a melanocortin 4 receptor (mc4-r) compared to normal physiological conditions. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance α-msh activity..
Orexigen Therapeutics, Inc.

Pharmaceutical compositions for combination therapy

This invention relates to the use of pharmaceutical compositions comprising a therapeutically effective combination of tesofensine and metoprolol for preventing the cardiovascular side effects of tesofensine, while leaving the robust inhibitory efficacy on food intake and body weight loss unaffected.. .
Saniona A/s

Polyoxalates and a process for the production thereof

A polyoxalate containing, as a chief constituent unit, a recurring unit represented by the following formula (1): —(—co—co—o-a-o—)n— wherein n is a positive number, and a is a divalent organic group, and having a quantity of heat of fusion Δhm of not less than 60 j/g as measured by dsc in the first time of elevating the temperature, thereby permitting the components to be volatilized in an amount of not more than 2.0% by weight when the temperature is elevated up to 200° c. As measured by the tga, and having a 5% weight loss temperature (td5%) of not higher than 230° c.
Toyo Seikan Group Holdings, Ltd.

Brown adipocyte modification

Methods and therapeutics are provided for treating metabolic disorders by increasing activation of brown adipose tissue. Generally, the methods and therapeutics can increase activation of brown adipose tissue to increase energy expenditure and induce weight loss.
The General Hospital Corporation D/b/a Massachusetts General Hospital

Implantable prosthetic device for weight loss in an obese or overweight patient comprising an inflatable gastric balloon and a duodenal prosthesis

According to the invention, such a device is characterized in that it comprises a system for coupling said balloon to said duodenal prosthesis; said duodenal prosthesis is compressible and expandable in a radial direction; said prosthesis has a wall that is fixedly attached, on at least one part of its length, to a helical frame and said helix has an irregular pitch.. .

Calorie optimization respiratory exchange (core) metabolic profile system and method

The disclosed embodiments include a calorie optimization respiratory exchange metabolic system comprising a computer-readable storage media having stored thereon computer-executable instructions; a processor for executing the computer-executable instructions, wherein the computer-executable instructions include instructions for receiving user profile data of a user, wherein the user profile data includes age, height, weight, diet, and fitness information; determining five metabolic points versus heart rate; generating an individualized metabolic profile for the user based on the five metabolic points; determining for the user an individualized nutritional guideline from the metabolic profile, wherein the individualized nutritional guideline is determined by percent fat, percent protein and percent carbohydrate to optimize fat metabolism for weight loss, maintenance, and endurance exercise enhancement; and determining an individualized exercise heart rate profile as a percentage of maximum heart rate from the metabolic profile.. .
Core Metabolics Llc

Weight loss floor mat

A floor mat configured to encourage weight loss through the use of a timer, an alarm, and/or one or more weighing devices. The device is specifically designed to look like an ordinary floor mat in appearance, size and texture and will include a processor that can receive a signal from the user and in response the processor can activate a timer and/or an alarm.

Devices and methods for treating the gastrointestinal system

Devices and methods for less invasively treating the gastrointestinal system, such as the intestinal mucosa of the small bowel. Embodiments described herein may be used to reduce caloric absorption and effectuate weight loss, for example..
Bridgepoint Medical, Inc.

Compounds for the treatment of obesity and methods of use thereof

weight loss agents include compounds defined by formula i or a pharmaceutically acceptable salt or prodrug thereof, compositions containing the same, and methods of use thereof are described herein. In some embodiments, the compound is withaferin a.
The Children's Medical Center Corporation

Hunger minimized juice fasting system

The hunger minimized fasting system relies on providing a blood glucose level at all times in the range of 5 to 10 mm, satisfying glucose needs of the brain and metabolizing blood glucose through anaerobic glycolysis to release atp at the extramitocontrial portion of the cell. Consuming only solid free nutrient liquids eliminates brain hunger response.

Method of reducing calorie intake in a pet

The present invention relates to a nutritionally complete pet food product comprising at least two compositions for use in a method of reducing calorie intake in a companion animal, wherein the compositions differ in their level of fat, protein or carbohydrate on an energy ratio basis by 6% to 50% and wherein the compositions are consumed on consecutive days, each composition being consumed on a different day. The invention also relates to such a food product in the prevention of weight gain after surgical procedures to neuter a companion animal, and also to the food product in a weight loss regime.
Mars, Incorporated

Pro-neurogenic compounds

This technology relates generally to compounds and methods for stimulating neurogenesis (e.g., post-natal neurogenesis, including post-natal hippocampal and hypothalamic neurogenesis) and/or protecting neuronal cell from cell death. Various compounds are disclosed herein.
Board Of Regents Of The Univeristy Of Texas System

Glucagon analogues

The invention provides glucagon analogue peptides and their use for promoting weight loss or preventing weight gain, and the treatment of obesity or excess body weight and associated conditions. The compounds may also be used to improve glycemic control and/or for the treatment of diabetes.
Boehringer Ingelheim International Gmbh

Metap2 inhibitors and methods of treating obesity

The present invention relates to modified or polymer conjugated metap2 inhibitors. The present invention also relates to methods of preventing, inducing, causing or increasing weight loss, treating obesity and/or treating metabolic syndrome utilizing the modified or polymer conjugated metap2 inhibitors.
Syndevrx, Inc.

Methods and compositions for using cinnamaldehyde and zinc for weight management

Compositions comprise an amount of cinnamaldehyde that is orally tolerable, thus avoiding an unpleasant mouth feeling, and also tolerable in the gastrointestinal tract. The amount of cinnamaldehyde is supplemented by zinc, and the combination is effective to increase at least one of energy expenditure, sympathetic nervous system activity, or fat oxidation, relative to a composition lacking cinnamaldehyde and zinc but otherwise identical.
Nestec S.a.

Compositions and methods for modulating metabolic pathways

Compositions and methods useful for inducing an increase in fatty acid oxidation or mitochondrial biogenesis, reducing weight gain, inducing weight loss, or increasing sirt1, sirt3, or ampk activity are provided herein. Such compositions can contain synergizing amounts of a sirtuin-pathway activators, including but not limited to resveratrol, in combination with beta-hydroxymethylbutyrate (hmb), keto isocaproic acid (kic), leucine, or combinations of hmb, kic and leucine..
Nusirt Sciences, Inc.

Stearoyl amino acid salt and preparation method and application thereof

A stearoyl amino acid salt having a structural formula of the general formula (i), wherein r1 is h or an aromatic base capable of being substituted by one or more substituents, or a c1-4 straight chain or an alkyl with a branched chain, the substituent being an alcoholic hydroxyl group or a phenolic hydroxyl group; and r2 is a c11-25 saturated or unsaturated aliphatic group. Also provided are methods of preparing the stearoyl amino acid salt, and methods of using the stearoyl amino acid salt.
Shanghai Jiaotong University School Of Medicine

System, post-operative bariatric weight loss performance tracking

A mobile application for a mobile computing device that charts a patient's weight loss after a bariatric surgical procedure compared to a reference curve. By having a reference curve for the patient to conduct a self-comparison, the app can potentially encourage the user to try harder to either meet or beat the average weight loss over time, resulting in improved results for the patient..

Oxidized carbon blacks and applications for lead acid batteries

Disclosed herein are oxidized carbon blacks, which can be incorporated into electrode compositions for lead acid batteries. In some embodiments, the oxidized carbon blacks have a bet surface area ranging from 650 to 2100 m2/g; an oil absorption number (oan) ranging from 35 to 500 ml/100 g; and a volatile content of at least 5.5 wt.
Cabot Corporation

Probiotic compositions and methods for inducing and supporting weight loss

A probiotic composition for inducing or supporting weight loss in a subject, the probiotic composition including an effective amount of a bacteria selected from the genus bacteroides and a carrier for delivering the bacteria to the subject.. .

Low dose topiramate/phentermine composition and methods of use thereof

A method for effecting weight loss by administering a combination of topiramate and phentermine is provided. The phentermine is generally administered in immediate release form, in a daily dose in the range of 2 mg to 8 mg, in combination with a daily dose of topiramate selected to prevent the loss of effectiveness of phentermine alone.
Vivus, Inc.

Glucagon analogues

The invention provides materials and methods for promoting weight loss or preventing weight gain without affecting glycemic control. In particular, the invention provides novel glucagon analogue peptides effective in such methods.
Zealand Pharma A/s

Methods and compositions for increasing energy expenditure using cinnamaldehyde

Compositions comprise an amount of cinnamaldehyde that is orally tolerable, thus avoiding an unpleasant mouth feeling, and also tolerable in the gastrointestinal tract. The amount of cinnamaldehyde is effective to increase at least one of energy expenditure, sympathetic nervous system activity, or fat oxidation, relative to a composition lacking cinnamaldehyde but otherwise identical.
Nestec S.a.

Intra-oral device for treating obesity

The present invention relates to an intra-oral device including a carrier that has an outside wall, an inside wall and an occlusal wall connecting the outside wall to the inside wall. The carrier has at least one inset and at least one insert carrying a beneficial agent that is adapted to fit the inset, and the beneficial agent is capable of promoting weight loss.
Dynamic Mouth Devices, L.l.c.

Fabrication of a flexible metal-clad laminate

The present disclosure relates, according to some embodiments, to a method of fabricating a flexible metal-clad laminate comprising forming a metal layer on a surface of a polyimide film, wherein the metal layer and the polyimide film are contacting each other and forming a laminate, and heating the laminate at a temperature of about 80° c. To about 140° c.
Arakawa Chemical Industries, Ltd.

Weight loss formulations, methods, and compositions based on traditional chinese medicine

The present invention relates to formulations made up from extracts from ganoderma lucidum, rhizome of coptis chinensis, radix astragali, nelumbo nucifera gaertn, chaenomeles speciosa, and fructus aurantii. Pursuant to the invention, the formulations are used to treat obesity and the biological sequelae of obesity including cholesterol levels and glucose levels.

Pressure-sensitive adhesive tape

This invention provides a pressure-sensitive adhesive tape that comprises a polyvinyl chloride film comprising a plasticizer and a pressure-sensitive adhesive layer placed at least on one face of the film. The pressure-sensitive adhesive tape has a weight loss on heating of less than 4% and a holding power of 50 minutes or greater..
Nitto Denko Corporation

Compounds

The present invention relates to compounds which are capable of exerting an inhibitory effect on the na+ glucose cotransporter sglt in order to hinder glucose and galactose absorption, as well as on lipase thus reducing dietary triglyceride metabolism, for use in the treatment of conditions which benefit therefrom (diabetes. Metabolic syndrome, obesity, prevention of weight gain or aiding weight loss).

Compositions and methods for increasing energy metabolism

Compositions and methods useful for inducing an increase in fatty acid oxidation or mitochondrial biogenesis, reducing weight gain, inducing weight loss, or increasing sirt1, sirt3, or ampk activity are provided herein. Such compositions comprise a combination of a pde 5 inhibitor, such as sildenafil or icariin, and resveratrol, and a branched amino acid such as leucine, or its metabolite..
Nusirt Sciences, Inc.

Estrogen receptor modulators for reducing body weight

The present invention relates to a method of reducing the body weight of a subject by administering an effective amount of an estrogen receptor modulator (erm), optionally, in combination with an anti-obesity or weight loss agent.. .
Rosscreening, Inc.

Magnetic satiety-inducing system

A minimally invasive system and method for providing weight loss by inducing the feeling of satiety whereby an intragastric device is inserted into the gastric lumen via the esophagus and an external magnetic device is used as needed to magnetically attract the intragastric device towards the inner wall of the stomach and impart tactile stimulation sufficient to induce the feeling of satiety.. .

Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies

The present invention relates to matriptase antibodies and immunoconjugates of matriptase antibodies with cytotoxic agents and the use thereof for killing or inhibiting the growth of matriptase-expressing cancer cells, such as those of multiple myeloma and breast cancers. In particular, immunoconjugates comprising a matriptase monoclonal antibody and anticancer agents such as auristatin, including monomethyl auristatin e (mmae) and monomethyl auristatin f (mmaf) are introduced, which have potent antitumor activity in vivo.
Georgetown University

Nutrition-balancing containers and use

A four step system for weight loss in a person who is overweight or obese by introducing protein, vegetable, and starch (carbohydrate) in specific ratios to promote fat utilization and weight loss from fat composition of the person's entire body. The system utilizes portion control meal plates for weight loss in an overweight or obese person that have different protein, vegetable, and starch (carbohydrate) intake portions..

Powder sintered metallic porous body, filter element and improving permeability thereof

Disclosed are a powder sintered porous metal with better comprehensive properties, especially with good corrosion resistance to hydrofluoric acid, and a filter element using same. The powder sintered porous metal of the present invention has a porosity of 25-60%, an average pore diameter of 0.5-50 μm and a weight loss rate of at most 1% after being immersed into a hydrofluoric acid solution with a mass fraction of 5% at room temperature for 20 days; and the powder sintered metal porous body consists of cu accounting for 23-40 wt %, si accounting for 0-5% and the balance of ni, based on the weight of the powder sintered metal porous body.
Intermet Technologies Chengdu Co., Ltd

Escalating dosing regimen for effecting weight loss and treating obesity

The present invention is drawn to novel topiramate compositions as well as methods for effecting weight loss, e.g., in the treatment of obesity and related conditions, including conditions associated with and/or caused by obesity per se. The present invention features an escalating dosing regimen adapted for the administration of topiramate and optionally a sympathomimetic agent such as phentermine or bupropion, in the treatment of obesity and related conditions..
Vivus, Inc.

Monoacylglycerols for use in conjunction with a lipase inhibitor and/or diets low in fat and/or calories

In an embodiment, compositions comprising monoacylglycerols (mag), such as sn-1(3) mag, are administered with a lipase inhibitor, such as tetrahydrolipstatin, and/or with a diet low in fat and/or calories. In another embodiment, compositions comprising mag, such as sn-1(3) mag, are administered concurrently with a lipase inhibitor, such as tetrahydrolipstatin, and/or with fat-soluble nutrients.
Nestec S.a.

Electrically heated blanket with sleep depth -dependent control- for weight loss

An electric blanket is controlled so that it initially provides cozy warmth at low ambient temperature, but on reaching deep sleep phases, temperature is lowered, for as much dissipation of calories as it does not disrupt the sleep.. .

Carcass weight control

Provided, is a fully integrated system to monitor and control carcass weight to minimize weight loss in carcasses during the chilling cycle. This will be accomplished by incorporating a load cell and a radio frequency identification device on the trolley operating on the elevated track system extending through the packing plant, including the carcass chilling rooms.
Lp Solutions Llc

Sintered porous material and filter element using same

Disclosed is a sintered porous material with stronger corrosion resistance and a filter element using same. The sintered porous material of the present application has following features: a) it mainly consists of three elements of ti, si and c, and the total weight of the three elements accounts for at least 90% of the weight of the sintered porous material, wherein ti is 60-75% of the total weight of ti, si and c, and si is 10-20% of the total weight of ti, si and c; b) c in the sintered porous material is mainly present in the form of the ti3sic2 ternary max phase compound, and is almost uniformly dispersed in the porous material; c) the porous material has porosity of 30-60%, average pore size of 0.5-50 μm, tensile strength of at least 23 mpa, pure water filtration flux of 1 t/m2·h at least measured under a filtration pressure difference of 0.05 mpa with a thickness of 5 mm at most for the sintered porous material, and a weight loss rate of at most 1.5% after being immersed into a 5 wt.
Intermet Technologies Chengdu Co., Ltd

Sintered fe-al based porous alloy material with high-temperature oxidization resistance and filtering elements

Disclosed are a sintered fe—al based alloy porous material with high temperature oxidation resistance and a filter element using same. The porous material has a porosity of 30-60% and an average pore diameter of 0.5-50 μm, and has that: a) it mainly consists of three elements of fe, al and cr, and the total weight of these three elements accounts for at least 90% of the weight of the porous material, wherein the weight of fe is 60-85% of the total weight of fe and al, and the weight of cr is 10-30% of the total weight of fe, al and cr; b) the cr in the porous material mainly presents in the form of a chromium compound of a fe—al based compound, or mainly presents in the form of a chromium compound of the fe—al based compound and fecr, and is almost uniformly dispersed in the porous material; and c) it has a tensile strength ≧45 mpa, an air flux ≧80 m3/m2·kpa·h for the sintered fe—al based alloy porous material with a thickness ≦5 mm, a weight loss rate of at most 0.5% after being immersed into a naoh solution with a mass fraction of 10% at room temperature for 15 days, and a material weight gain rate of at most 0.25% after being kept at 1000° c.
Intermet Technologies Chengdu Co., Ltd

Compositions and methods for chronic use of a weight-gaining compound

Provided herein is a method of treating weight loss in one or more companion animals or livestock. The method can provide administering a therapeutically effective amount of a capromorelin-containing composition to a companion animal or livestock in need thereof for a period of at least 30 days.
Aratana Therapeutics, Inc.

Anti-depression compounds

This technology relates generally to compounds and methods for stimulating neurogenesis (e.g., post-natal neurogenesis, including post-natal hippocampal and hypothalamic neurogenesis) and/or protecting neuronal cell from cell death. Various compounds are disclosed herein.
Board Of Regents Of The University Of Texas System

Control mixing controlled atmosphere storage of fruit vegetables on oceangoing ships

The invention achieves control over mixing controlled atmosphere storage of fruit vegetables by preparing an air-conditioned cold store, selecting fruits and vegetables, precooling, and stacking. Fruits and vegetables, upon pickup.
Wuxi Delin Marine Equipment Co. Ltd.

Methods for administering weight loss medications

Methods and systems for administration of pharmaceuticals using a unit dosage package that includes a first unit dosage that has a first drug and a second drug, a second unit dosage that has the first drug and the second drug, where the second unit dosage includes a different amount of the second drug than the first unit dosage and a unit dosage package is configured to hold the first unit dosage and the second unit dosage. In preferred embodiments the methods and systems are used for administration of weight loss medications..
Orexigen Therapeutics, Inc.

Methods and monitoring and encouraging health and fitness

Methods and apparatus are provided for monitoring and encouraging health and fitness. In accordance with a first aspect, an apparatus is provided that is adapted to assist in weight loss and exercise.

Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides

Methods are provided for administering an extended half-life glp-1/gip coagonist peptide to a patient in need thereof for reducing weight gain, inducing weight loss, treating hyperglycemia, reducing blood glucose levels, or normalizing blood glucose levels in said patient.. .

Citrate resorption of bone as a treatment for spinal stenosis

Spinal stenosis is a common debilitating illness that produces symptoms of neurogenic claudication, radiculopathy and weakness. Present therapies include administration of analgesics, epidural injections of local anesthetic with corticosteroids and decompression laminectomy.

Athletic pants for producing sweat in targeted areas

An athletic pants for use by a user to enhance sweat production in targeted areas of a lower body region promotes weight loss. The athletic pants include a breathable garment that conforms to the lower body region of the user and has a front panel coupled to a rear panel, each panel having an upper waist portion attached to an intermediate portion, and a pair of lower leg portions coupled to the intermediate portion, and at least one non-breathable member coupled to an interior portion of the breathable garment proximate at least one targeted area of the lower body region of the user.

Pressure sensitive adhesive foam

The present disclosure relates to a pressure sensitive adhesive foam comprising a rubber-based elastomeric material and at least one hydrocarbon tackifier, wherein the hydrocarbon tackifier(s) have a volatile organic compound (voc) value of less than 1000 ppm and a volatile fogging compound (fog) value of less than 1500 ppm, when measured by thermogravimetric analysis according to the weight loss test methods described in the experimental section. The present disclosure also relates to a method of manufacturing such a pressure sensitive adhesive foam and uses thereof..
3m Innovative Properties Company

Methods of providing weight loss therapy in patients with major depression

Disclosed are methods of providing weight loss therapy, particularly for patients suffering from major depression.. .
Orexigen Therapeutics, Inc.

Methods and compositions for preserving lean body mass and promoting fat loss during weight loss

The invention provides compositions and methods for preserving lean body mass and promoting fat loss during weight loss. The methods comprise identifying an animal that is obese or overweight and administering to the animal a food composition in an amount less than the animal's baseline maintenance energy requirement (mer), the food composition comprising from about 30% to about 65% protein, from about 10% to about 20% carbohydrate, and from about 10% to about 25% fat; where the protein and carbohydrate are in a ratio effective for preserving lean body mass and promoting fat loss during administration of the food composition to the animal..
Nestec Sa

Water/oil-repellent treatment agent having heat resistance, preparation, and treated article

A water/oil repellent treatment agent which includes a specific polymer-modified silane having a fluorooxyalkylene structure on the main chain and a hydrolyzable group at the end of the molecular chain, and/or a partial (co)hydrolyzate/condensate thereof, has a percent weight loss following one hour of exposure at 250° c. Of 10% or less.
Shin-etsu Chemical Co., Ltd.

Methods and compositions for the treatment of body weight related disorders

The present invention relates to methods for reducing body weight in an animal in need thereof via administration of a therapeutically effective amount of a compound having a general tripartite structure a-b-c. In the tripartite structure a, b, and c are identical or non-identical structures, for example, but not limited to, heterocyclic, phenyl or benzyl ring structures with or without substitutions and are described in detail herein.
Baylor College Of Medicine

Muscle preservation in overweight or obese adult during weight loss program

The invention pertains to the use of a composition comprising per serving between 50-300 kcal; between 10 g and 35 g proteinaceous matter; and at least 2.5 microgram vitamin d, for the manufacture of a nutritional product for (a) the treatment or prevention of muscle mass decrease, (b) stimulation of muscle mass increase; or (d) stimulating muscle mass preservation, in obese or overweight adults of at least 40 years of age participating in a weight loss program. The inventors surprisingly found that nutritional supplementation with a low-caloric composition rich in protein, particularly whey protein and leucine, compared to an iso-caloric control supplement without protein, synergistically leads to preservation of muscle mass during a weight loss program involving a hypocaloric diet and a resistance exercise program in overweight/obese older adult..
N.v. Nutricia

Acylated glucagon analogues

The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes and associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods.
Zealand Pharma A/s

Information processing system, program, and information processing method

An information processing system 100 includes an information acquiring unit 110 that performs acquisition processing for information, a processing unit 120 that performs processing on the basis of the acquired information, and an output processing unit 130 that performs output processing for information created by the processing unit 120. The information acquiring unit 110 performs the acquisition processing for at least two kinds of information among staying time information, body information, and target information concerning a weight loss.
Seiko Epson Corporation

Apparatus and methods for corrective guidance of eating behavior after weight loss surgery

Apparatuses and methods for corrective guidance of eating behavior of a patient equipped with a gastric restriction device. The apparatus provides continuous monitoring or one or more parameters related to food passing through the gastric restriction device.

Compositions and methods for modulating metabolic pathways

Compositions and methods useful for inducing an increase in fatty acid oxidation or mitochondrial biogenesis, reducing weight gain, inducing weight loss, or increasing sirt1, sirt3, or ampk activity are provided herein. Such compositions can contain synergizing amounts of a sirtuin-pathway activators, including but not limited to resveratrol, in combination with beta-hydroxymethylbutyrate (hmb), keto isocaproic acid (kic), leucine, or combinations of hmb, kic and leucine..
Nusirt Sciences, Inc.

Satiation devices and methods

A device for inducing weight loss in a patient includes a tubular prosthesis self-expandable from a collapsed position in which the prosthesis has a first diameter to an expanded position in which the prosthesis has a second, larger, diameter. In a method for inducing weight loss, the prosthesis is placed in the collapsed position and inserted into a stomach of a patient.
Boston Scientific Scimed, Inc.

Petroselinic acid or a combination of active ingredients comprising at least petroselinic acid for promoting weight loss and/or weight maintenance

The present invention relates to the field of weight management and obesity. It concerns petroselinic acid or a combination of active ingredients including at least petroselinic acid and at least one compound chosen from zinc, taurine, one of the salts of same, lycopene and the mixtures thereof, and preferably at least taurine or zinc gluconate and, more preferably still, at least taurine and zinc gluconate, as a drug for oral administration or as a functional food intended to promote weight loss and/or weight maintenance in a human being and/or animal, or indeed intended to fight obesity..

Apparatus and methods for corrective guidance of eating behavior after weight loss surgery

Apparatuses and methods for corrective guidance of eating behavior of a patient equipped with a gastric restriction device. The apparatus provides continuous monitoring or one or more parameters related to food passing through the gastric restriction device.

Hunger minimized juice fasting system

The hunger minimized fasting system relies on providing a blood glucose level at all times in the range of 5 to 10 mm, satisfying glucose needs of the brain and metabolizing blood glucose through anaerobic glycolysis to release atp at the extramitocontrial portion of the cell. Consuming only solid free nutrient liquids eliminates brain hunger response.

Compositions and methods for treating metabolic disorders

Methods for improving the gastrointestinal tolerability of biguanide compounds and for treating metabolic disorders and/or inducing weight loss in patients in need thereof, particularly in individuals having a contraindication for treatment with biguanide compounds, are provided comprising administering delayed release formulations of such biguanide compounds, including metformin, targeted to the small intestine.. .
Elcelyx Therapeutics, Inc.

Use of vitamin k for weight maintenance and weight control

Vitamin k is effective in counteracting (1) increase of body weight and body mass index (bmi), (2) accumulation of body fat mass and (3) accelerates weight loss during calory restriction or other life style interventions aiming weight reduction. A pharmaceutical composition or nutritional formulation comprising vitamin k is provided which can be used to combat overweight or obesity, either as a single, dedicated product or in combination with other slimming products or life style changes..
Vitak B.v.

Manufacturing cathode material, cathode, and lithium ion battery

A cathode material which does not easily deteriorate when used in batteries, a method for producing cathode materials, a cathode, and a lithium ion battery are provided. A cathode material including a cathode active material, in which the cathode active material is expressed by li1+xaydzpo4 (here, a represents one or more metal elements selected from the group consisting of co, mn, ni, fe, cu, and cr, d represents one or more metal elements selected from the group consisting of mg, ca, sr, ba, ti, zn, b, al, ga, in, si, ge, sc, y, and rare earth elements, 0<x<1, 0<y<1, 0≦z<1.5, and 0.9<y+z≦1), and, in thermogravimetric analysis in an inert gas atmosphere, when a temperature is increased in a temperature range from 100° c.
Sumitomo Osaka Cement Co., Ltd.

Lachnospiraceae in the gut microbiota and association with body weight

The present invention relates to means and methods for modulating the gut microbiota composition of a subject, preferably a human. In particular, the present invention provides an agent capable of reducing the proportion of lachnospiraceae in the gut microbiota composition of a subject which agent is useful for promoting weight loss or preventing weight gain in a subject, preferably an obese or overweight subject.
Nestec S.a.

Removable vascular occlusion device

Disclosed herein are embodiments of an occlusion device that can be delivered into the vascular system of a patient for inducing weight loss. The device can be formed from a body that can expand from a collapsed to an expanded position, where the body can be configured to at least partially occlude a blood vessel.
Anaxiom Corporation

Anti-gdf15 antibodies

Monoclonal antibodies that bind and inhibit the activity of human gdf15 are disclosed. The antibodies can be used to treat body weight loss, including cachexia, associated with the over-expression of human gdf15..
Aveo Pharmaceuticals, Inc.

Nutritional composition and manufacture

A nutritional composition, and method of making it, that includes a carbohydrate, an insulin potentiator, an amino acid, a muscle growth stimulator, an energy increaser, at least one natural supplement for weight loss, reduction of cholesterol levels, and/or increased resistance to stress, and at least one flavoring ingredient. The composition may be provided in dry form for addition to a fluid or in liquid forms.

Process

A method for reducing the amount of cholesterol and/or improving the texture and/or reducing weight loss and/or increasing the fat stability of a meat based food product comprising: a) contacting meat with a lipid acyltransferase; b) incubating the meat contacted with the lipid acyltransferase at a temperature between about 1° c. To about 70° c.; c) producing a food product from the meat; wherein step b) is conducted before, during or after step c).
Dupont Nutrition Biosciences Aps

Pro-neurogenic compounds

This technology relates generally to compounds and methods for stimulating neurogenesis (e.g., post-natal neurogenesis, including post-natal hippocampal and hypothalamic neurogenesis) and/or protecting neuronal cell from cell death. Various compounds are disclosed herein.
Board Of Regents Of The University Of Texas System

Pharmaceutical compositions for combination therapy

This invention relates to the use of pharmaceutical compositions comprising a therapeutically effective combination of tesofensine and metoprolol for preventing the cardiovascular side effects of tesofensine, while leaving the robust inhibitory efficacy on food intake and body weight loss unaffected.. .
Saniona A/s

Systems and monitoring an individual's compliance with a weight loss plan

A computer-implemented method, and related system, for monitoring the wellbeing of an individual by providing eyewear that includes at least one sensor for monitoring the motion of the user. In various embodiments, the system receives data generated by the at least one sensor, uses the data to determine the user's movements using the received data, and compares the user's movements to previously established movement patterns of the user.
Vision Service Plan

Compositions and methods for producing elevated and sustained ketosis

Beta-hydroxybutyrate mineral salts in combination with medium chain fatty acids or an ester thereof such as medium chain triglycerides were used to induce ketosis, achieving blood ketone levels of (2-7 mmol/l), with or without dietary restriction. The combination results in substantial improvements in metabolic biomarkers related to insulin resistance, diabetes, weight loss, and physical performance in a short period of time.
University Of South Florida

Weight loss device

A weight loss device including at least one peripheral plate that can be fixed to at least one portion of an upper dental arch or lower dental arch by fixing means, in a fixing configuration. The peripheral plate supports, by way of supporting elements, at least one central plate, which is adapted, in the fixing configuration, to rest against the palate or the floor of the mouth in order to limit the movements of the tongue inside the mouth..

Nutrition-pedometer

A system for determining the health and wellness of an individual user, the said system comprising a measuring device configured to measure and calculate (a) nutritional value of food items consumed, and (b) certain physical activities of the user, wherein the measuring device calculates and displays the weight gain or weight loss.. .

Low dielectric constant polymer containing dinaphthyl and hexafluorocyclobutyl ether unit, preparation method and use

The present invention belongs to the field of preparation of high performance polymers, and specifically relates to a low dielectric constant polymer containing dinaphthyl and hexafluorocyclobutyl ether units, and preparation method and use thereof. The polymer is prepared as follows: under the effect of an alkali, 1-naphthol bromotetrafluoroethane ether is prepared from 1-naphthol and tetrafluorodibromoethane in an organic solvent, and then reduced by a zinc powder so as to obtain 1-naphthol trifluorovinyl ether.
Shanghai Institute Of Organic Chemistry, Chinese Academy Of Sciences

Preconception/prenatal/postnatal optimal nutrition system, compositions and kits for use therein, and methods of making and using same

A nutrition system for use during a preconception period, during pregnancy, during lactation, and/or during postnatal weight loss is disclosed herein. Also disclosed are compositions and kits for use therein, as well as methods of making and using same.
Nestec S. A.

Methods and monitoring and encouraging health and fitness

Methods and apparatus are provided for monitoring and encouraging health and fitness. In accordance with a first aspect, an apparatus is provided that is adapted to assist in weight loss and exercise.

Weight loss formulation

A weight loss product comprises a mixture of alchemilla vulgaris, olea europaea, cuminum cyminum, and mentha longiflora (in the weight proportion 12:10:5:4), to which additional ingredients have been added to increase weight loss efficacy. The additional ingredients may include, but are not limited to, gamma-oryzanol, caffeine, cirsimarin, fucoxanthin, guggulsterones, evodiamine, forskolin, sclareolide, chromium, hydroxycitric acid, pinolenic acid, conjugated linoleic acid, potato protein, raspberry ketone, capsaicin, synephrine, dehydroepiandrosterone, phenylethylamine, orlistat, glucomannan, or vitamin c, or sources thereof, as well as herbal ingredients such as guarana, yerba mate, damiana, green tea, green coffee bean, cinnamon, white kidney bean, garcinia cambogia, nopal cactus, hoodia, yohimbine, malpighia glabra, eurycoma longifolia, caralluma fimbriata, citrus aurantium, gymnema sylvestre, lyceum barbarurn, aloe vera, cayenne, pomegranate, blueberry, billberry, or extracts of such herbal ingredients, and plant sources of antioxidants.
Northern Innovations And Formulations Corp.

Methods of mitigating side effects of radiation exposure and chemotherapy

Compositions and methods for treating toxicity associated with exposure to radiation and side effects of treatments for hyperproliferative disorders are provided. Typically the compositions are administered in an effective amount reduce one or more adverse side effects.
Gencia Corporation

Non-aqueous electrolyte secondary battery

The present invention provides a non-aqueous electrolyte secondary battery including a positive electrode, a negative electrode having a negative active material, and a non-aqueous electrolyte, characterized in that the negative active material contains composite particle (c), which has silicon-containing particle (a) and electronic conductive additive (b), the silicon-containing particle (a) has a content of carbon, and when measured at a temperature rising rate of 10±2° c./min by thermogravimetry, said composite particle (c) exhibits two stages of weight loss in the range of 30 to 1000° c.. .
Gs Yuasa International Ltd.

Polyphenylene sulfide resin composition, molded product of polyphenylene sulfide resin composition and production polyphenylene sulfide resin composition

There is provided a polyphenylene sulfide resin composition, comprising 5 to 95% by weight of a component (b) which is a polyphenylene sulfide resin having a weight-average molecular weight of not less than 10,000 and a weight loss percentage Δwr of not greater than 0.18% under heating, relative to 95 to 5% by weight of a component (a) which is a polyphenylene sulfide resin having the weight loss percentage Δwr of greater than 0.18%, wherein a total of the component (a) and the component (b) is equal to 100% by weight.. .
Toray Industries, Inc.

Aminic hardeners with improved chemical resistance

A hardener composition comprising: a) an epoxy-amine adduct of i) a novolac epoxy resin; and ii) a first amine and b) a modifier wherein the hardener has a viscosity in the range of from 50 to 20,000 mpa·s and wherein a cured epoxy thermoset comprising the hardener exhibits no more than 1% weight loss or gain after immersion in concentrated mineral acid for 7 days at a temperature in the range of from 25° c. To 130° c., is disclosed.
Blue Cube Ip Llc

Escalating dosing regimen for effecting weight loss and treating obesity

The present invention is drawn to novel topiramate compositions as well as methods for effecting weight loss, e.g., in the treatment of obesity and related conditions, including conditions associated with and/or caused by obesity per se. The present invention features an escalating dosing regimen adapted for the administration of topiramate and optionally a sympathomimetic agent such as phentermine or bupropion, in the treatment of obesity and related conditions..
Vivus, Inc.

S-enantiomerically enriched compositions of beta blockers for treating amyotrophic lateral sclerosis

The present invention relates to s-enantiomerically enriched compositions of beta blockers and uses thereof, including uses of the beta blocker compositions for treating amyotrophic lateral sclerosis. The beta blocker compositions can also be used for preventing loss of lean mass, preventing body weight loss in subjects, improving quality of life in subjects, and prolonging survival in amyotrophic lateral sclerosis patients.
Charite - Universitaetsmedizin Berlin

Oxprenolol compositions for treating cancer

The present invention relates to compositions of s-enantiomer enriched oxprenolol and their use in treating cancer and treating or preventing, in cancer patients, cachexia, body weight loss, lean body mass loss and adipose tissue loss, and improving quality of life and prolonging survival of cancer patients.. .

Combination treatment comprising bupropion ( (±)-2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one) and a sympathomimetic drug for weight control and treating obesity

Compositions and methods for controlling weight gain and treating obesity are disclosed. Compositions include bupropion and a sympathomimetic drug.

Arterial constrictor for weight loss treatment

This document provides methods and devices involved in medical treatment of morbid obesity. For example, this document provides methods and devices for reducing the digestive efficiency of the intestines by decreasing the arterial blood supply to the intestines..
Motarless Technologies Llc

Muscular integral development system for resistance (midsyr)

A muscular integral development system for resistance (midsyr) to develop or exercise muscles of a body of an user. The system is directed to develop an area of the body or specific muscle group, such as for example the abdominals, pectorals, biceps, buttocks or leg muscles.

Electro-conductive paste with characteristic weight loss for high temperature application

Wherein the first weight loss Δ30 is in the range from about 0.05 to about 0.3 wt. %..

Electro-conductive paste with characteristic weight loss for high temperature application

Wherein the first weight loss Δ30 is in the range from about 0.05 to about 0.3 wt. %..

Corrosion inhibition

Corrosion of steel by aqueous acidic solution when treating a wellbore with acid is inhibited by a procedure in which the steel is initially exposed to a first aqueous solution containing one or more corrosion inhibiting constituents which provide both corrosion inhibitor and hydrophobic liquid and deposit a corrosion inhibiting film on the steel surface and then exposed to an acidic second aqueous solution containing one or more such corrosion inhibiting constituents at a lower concentration. During this second period, the lower concentration of corrosion inhibiting constituents in the second aqueous solution maintains the film already established on the steel surface.
Schlumberger Technology Corporation

Noninvasive facilitating weight loss

In accordance with one embodiment, an apparatus and method for facilitating weight loss are provided which constitute improvements over prior surgical treatments by providing a proven way to promote desirable weight loss in overweight patients through induced appetite reduction. The invention is comfortable enough to be used everyday without causing undue agitation to the wearer and provides measurable reductions in appetite and increased weight loss..

Polyester polyols imparting improved flammability properties

An aromatic polyester polyol having a nominal functionality of at least about 2 is produced from the esterification reaction of a phthalate-based composition containing less than 50 mol % of ortho-phthalic acid or phthalic anhydride, with a hydroxyl material containing at least 20 mol % of at least one branched aliphatic diol, and optionally transesterified with at least one hydrophobic material. The polyester polyol has improved shelf-life stability as demonstrated by the polyester polyol remaining clear and homogeneous for at least 6 months when stored at room temperature.
Stepan Company

Methods and compositions for treating obesity, preventing weight gain, promoting weight loss, promoting slimming, or treating or preventing the development of diabetes

The present invention relates to compositions and kits including a chemical uncoupler, such as tyrphostin 9 or precursor or a salt thereof, and compositions including a chemical uncoupler, such as tyrphostin 9 in combination with one or more therapeutic agents, for example, l-carnitine, which are useful, for example, in treating obesity, preventing weight gain, promoting weight loss/slimming, and/or treating or preventing the development of diabetes.. .
Nan Global, Llc

Glucagon analogues

The invention provides materials and methods for promoting weight loss or preventing weight gain and for treating diabetes and associated metabolic disorders. In particular, the invention provides novel glucagon analogue peptide compounds effective in such methods.
Zealand Pharma A/s

Controlling moisture in and plasticization of bioresorbable polymer for melt processing

Methods and systems for controlling the moisture content of biodegradable and bioresorbable polymer resin during extrusion above a lower limit that allows for plasticization of the polymer resin melt and below an upper limit to reduce or prevent molecular weight loss are disclosed. Methods are further disclosed involving plasticization of a polymer resin for feeding into an extruder with carbon dioxide and freon..
Abbott Cardiovascular Systems Inc.

Metap2 inhibitors and methods of treating obesity

The present invention relates to modified or polymer conjugated metap2 inhibitors. The present invention also relates to methods of preventing, inducing, causing or increasing weight loss, treating obesity and/or treating metabolic syndrome utilizing the modified or polymer conjugated metap2 inhibitors.
Syndevrx, Inc.

Aerated pet treat

The present invention provides for an aerated pet treat and a method for weight loss or weight control in pets. The aerated pet treat is preferably low in calories and fat, thus a low calorie pet treat and a low fat treat are also provided.
Mars, Incorporated

Fat cell destroying exercise device

A motorized belt and roller device utilizes pressure-applying rollers to facilitate weight loss. The belt is arranged to reciprocate over an extended distance, and to apply sufficient pressure via the rollers to cause breakdown of fat cells in the abdominal region.

Differential flow-meter for measuring the weight loss in haemodialysis treatments

A differential flow-meter for measuring the weight loss in dialysis treatments. The differential flow-meter is of the “thermal anemometer” type..
Medica S.p.a.

Compositions and methods for weight loss in at risk patient populations

The present disclosure relates to compositions, kits, uses, systems and methods related to naltrexone plus bupropion for treating an overweight or obese subject at increased risk of adverse cardiovascular outcomes. Preferably, the subject has had type-two diabetes for a period of less than 6 years or is a current smoker, optionally that does not have type-two diabetes..
Orexigen Therapeutics, Inc.

Methods of treating an overweight or obese subject

The disclosure herein generally relates to methods of treating an overweight or obese condition, and overweight- or obesity-related conditions. In one embodiment, the disclosure provides a method of treating an overweight or obese condition involving administering to the subject in need thereof, an amount of a pharmaceutical composition including a metap-2 inhibitory compound, or a salt, ester, or prodrug thereof, effective to result in weight loss in the subject..
Zafgen, Inc.

Composition for preventing or treating cachexia

The present invention relates to composition for preventing or treating cachexia, and more specifically, to a composition for preventing or treating cachexia containing a peptide derived from a telomerase. The composition for preventing or treating cachexia, according to present invention, has the advantages of improving symptoms of cachexia, such as weight loss, anemia, edema, and loss of appetite, and has few side effects..
Kael-gemvax Co., Ltd.

Methods and systems for treating overweight individuals

A system for inducing weight loss in an individual includes a collection having plurality of dose units therein. Each dose unit includes a first dose of phentermine or a second dose of phentermine.

Gastric implant and use of same

An implant device and method for inducing weight loss is provided wherein the implant device deforms the stomach wall thereby reducing the effective stomach volume without connection or access to the inner stomach. The implant device has a shape to provide for deformation of the stomach without retention within the inner stomach..

Hot-rolled steel sheet for producing non-oriented electrical steel sheet and producing same

By using a hot-rolled steel sheet of a predetermined chemical composition, and annealing the hot-rolled steel sheet in nitrogen atmosphere at 1000° c. For 30 seconds, and then immersing in a solution of 7% hcl at 80° c.
Jfe Steel Corporation

Compositions and methods for modulating metabolic pathways

Compositions and methods useful for inducing an increase in fatty acid oxidation or mitochondrial biogenesis, reducing weight gain, inducing weight loss, or increasing sirt1, sirt3, or ampk activity are provided herein. Such compositions can contain synergizing amounts of a sirtuin-pathway activators, including but not limited to resveratrol, in combination with beta-hydroxymethylbutyrate (hmb), keto isocaproic acid (kic), leucine, or combinations of hmb, kic and leucine..
Nusirt Sciences, Inc.

Dietary intervention with reduced daily caloric intake

The invention relates to various compositions for controlling body weight and/or for promoting weight loss. Examples of these compositions include but are not limited to formula i, formula i-vegan, formula ii, and formula iii.
Beachbody, Llc

Flavored chewable lipid supplements for maintaining health and the treatment of acute and chronic disorders

Flavored chewable wafers containing nutritional supplement formulations suitable for enhancement of cell and mitochondrial function as well as providing antioxidants and aiding in weight loss and other desirable nutritional benefits comprises enriched formulations of phospholipids, specifically identified concentrations of phosphatidylglycerol, phosphatidic acid, phosphatidylethanolamine, phosphatidylcholine, glycolipids and phosphatidylserine along with inulin and other desirable active ingredients. These edible wafer lipid combinations can be used to treat mitochondrial disorders and other nutritional deficiencies associated with medical pathologies, chronic illnesses and syndromes, or to maintain lipid balance for normal mitochondrial function, and can be administered in pleasant tasting chewable wafers..
Allergy Research Group, Llc

Low dosage combinations of fluoxetine and reboxetine for treating obesity

The present invention provides a pharmaceutical composition comprising a selective serotonin reuptake inhibitor (ssri) and a norepinephrine reuptake inhibitor (nri), particularly, fluoxetine and reboxetine, for treating obesity. Surprisingly, the inventor of the present invention discovered that use of especially low doses of the active compounds, particularly, at most 6 mg/day of reboxetine and at most 20 mg/day of fluoxetine, wherein the reboxetinerfluoxetine ratio is from about 1:4 to about 1:6, induces an effective weight loss in obese patients.

Methods of treating an overweight subject

The invention generally relates in part to methods of effecting weight loss and/or improving glucose tolerance in a patient in need thereof, comprising administering a metap2 inhibitor.. .
Zafgen, Inc.

Chromium and chlorogenic acid weight control formulations

This invention provides weight loss formulations and methods of use. The formulations include a combination of chlorogenic acids and chromium compounds.
Boresha International

Method for non-invasive stand alone high efficiency body weight loss and reduction of food intake

The present invention pertains to a method that effectively helps reducing body weight and food intake. The method includes self-administering and depositing into the stomach, via a capsule or similar carrier, various objects of various materials including an automatic self-inflating hygienic balloon or more, of various sizes, made of edible or non-harmful materials, by swallowing a capsule containing the balloon or the object, that self inflates to different pre-determined sizes, thus occupying a volume of stomach, hence reducing food intake and feeling of fullness.

Treatment for obesity by selectively clipping the gastric fundus to modify blood flow

weight loss can be promoted by folding a portion of the gastric fundus of a human subject's stomach in proximity to the distal portion of the subject's left gastric artery (including its smaller branches), and clipping the tissue so that it stays in the folded state. The clips cause endovascular flow reduction or interruption to the fundus.
Endobar Solutions Llc

Intermediate strength alloys for high temperature service in liquid-salt cooled energy systems

An alloy is composed essentially of, in terms of weight percent: 6 to 8.5 cr, 5.5 to 13.5 mo, 0.4 to 7.5 w, 1 to 2 ti, 0.7 to 0.85 mn, 0.05 to 0.3 al, 0.08 to 0.5 c, 0 to 1 nb, with the balance ni, the alloy being characterized by, at 850° c., a yield strength of at least 25 ksi, a tensile strength of at least 30 ksi, a creep rupture life at 12 ksi of at least 45 hours, and a corrosion rate, expressed in weight loss [g/(cm2 sec)]10−11 during a 1000 hour immersion in liquid flinak at 850 ° c., in the range of 6 to 39.. .
Ut-battelle, Llc

Uses of a gastrokine protein

Gastrokine-1 (gkn-1) is a stomach protein that protects the gastrointestinal (gi) tract and has properties to manipulate smooth muscle contraction, prevent nsaid-induced ulceration of the gastrointestinal tract of a mammal, inhibit growth and survival of cancer cells and induce weight loss in a mammal. Previously this protein was designated amp-18..
The University Of Chicago

Apparatus and methods for corrective guidance of eating behavior after weight loss surgery

Apparatuses and methods for corrective guidance of eating behavior of a patient equipped with a gastric restriction device. The apparatus provides continuous monitoring or one or more parameters related to food passing through the gastric restriction device.

Hmgi antibody for treating inflammatory conditions

There is disclosed a pharmaceutical composition and method for treating sepsis, including septic shock and ards (acute respiratory distress syndrome), comprising administering an effective amount of a hmg1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring the serum concentration of hmg1 in a patient exhibiting or at risk of exhibiting sepsis or septic shock symptoms.
The Feinstein Institute For Medical Research

Exercise cell, ketosis/weight loss inducing exercise machine (kwiem), ketosis inducing apparatus (kia)

A unique concept of exercise and weight loss that takes place in a new invention utility, namely the exercise cells or the ketone inducing apparatus is disclosed. The apparatus consists of four exercise cells to simulate four different exercise categories in extreme environments, namely walk/run/hike in a cold mountain environment, swim/water jogging in a cold water marine environment, cycling in a hot, humid, rainy, tropical forest environment, and gravitational rotation in a hot dry air windy space or desert environment.

Compositions and methods for increasing the suppression of hunger and reducing the digestibility of non-fat energy satiety

The present invention relates to methods for increasing the suppression of hunger and/or increasing the reduction of prospective consumption and/or increasing the reduction of appetite and/or increasing the feeling of satiety and/or reducing non-fat energy uptake in the gastrointestinal tract of a mammal in order to prevent a positive non-fat energy balance, weight gain, overweight and obesity, and to induce a negative non-fat energy balance and weight loss in subjects who wish to reduce their body weight. In particular, feed, food and/or beverages and dietary supplements of the present invention comprises mucilage such as flax seed 10 mucilage and/or one or more active compounds of mucilage useful for increasing the suppression of hunger and/or increasing the reduction of prospective consumption and/or increasing the reduction of appetite and/or increasing the feeling of satiety and/or reducing the digestibility of non-fat energy in the gastrointestinal tract of a mammal..
University Of Copenhagen

Method for treating obesity

The present invention relates generally to methods of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight loss-promoting anti-convulsant either alone or in combination with bupropion or metabolites thereof or other compound that enhances the activity of norepinephrine and/or dopamine via uptake inhibition or other mechanism.. .
Duke University

Methods and compositions for facilitating weight loss by administration of thyroid hormones

The present invention provides methods and compositions for facilitating weight loss in subjects who are undergoing a weight loss regimen by administration of thyroid hormones, for example, t2 alone, t2 in combination with t3, t2 in combination with t3 and t4, or t3 in combination with t4. In particular, subjects who have already experienced weight loss often are unable to continue to lose weight as the body experiences a famine response, i.e., hypothyroidism.

Satiation devices and methods

A device for inducing weight loss in a patient includes a tubular prosthesis self-expandable from a collapsed position in which the prosthesis has a first diameter to an expanded position in which the prosthesis has a second, larger, diameter. In a method for inducing weight loss, the prosthesis is placed in the collapsed position and inserted into a stomach of a patient.
Boston Scientific Scimed, Inc.

Candy and other carriers fortified with tea polyphenols or grape seeds extract

Candy, jelly, or other confections fortified with tea polyphenols, or grape seeds (skins) extract, serve as antioxidant or weight loss supplements. The combination affords at least four benefits, (1) continuously attracting consumer to ingest more antioxidants to get multiple benefits, (2) conveniently (handily) delivering plenty polyphenols to serve people in need, (3) masking the bitter taste of tea polyphenols, or grape seeds (skins) extract by a flexible formula, (4) improving the oral bioavailability..

Method for metabolic correction

A method of weight loss is disclosed having a weight loss phase including the steps of taking at least one glandular supplement daily, and eating a ketogenic diet.. .
Infinity Health Advisors, Llc

Low dose topiramate / phentermine composition and methods of use thereof

A method for effecting weight loss by administering a combination of topiramate and phentermine is provided. The phentermine is generally administered in immediate release form, in a daily dose in the range of 2 mg to 8 mg, in combination with a daily dose of topiramate selected to prevent the loss of effectiveness of phentermine alone.
Vivus, Inc.

High activity hydrotreating catalysts

This disclosure relates to supported multi-metallic catalysts for use in the hydrotreating of hydrocarbon feeds, as well as a method for preparing such catalysts. The catalysts are prepared from a catalyst precursor comprised of at least one group vib metal, at least one group viii metal and an organic acid.

Fat loss composition

Disclosed is a fat loss composition comprising a) a prostaglandin f2alpha analogue, such as cloprostenol, or a pharmaceutically acceptable ester or salt thereof; and b) amino acids 176-191 of human growth hormone. Use of the composition in weight loss, weight management and/or slimming is described..

Plant extract composition for inhibiting adipocytes, reducing body fat, promoting weight loss and increasing lipid metabolism as well as application thereof

The present invention provides a plant extract composition for inhibiting adipocytes, reducing body fat, losing body weight or increasing lipid metabolism, wherein the composition comprises 1.5 wt % to 40 wt % of resveratrol and 10 wt % to 85 wt % green tea extract. The composition not only provides high safety, but also effectively suppresses preadipocytes, inhibits differentiating adipocytes, inhibits mature adipocytes, increases the activity of carnitine acyl transferase-1, decreases body fat and promotes weight loss, and regulates the expression of the leptin gene and resistin gene..
Caliway Biomedical Co., Ltd.

Use of akkermansia for treating metabolic disorders

The present invention relates to akkermansia muciniphila or fragments thereof for treating a metabolic disorder in a subject in need thereof. The present invention also relates to a composition, a pharmaceutical composition and a medicament comprising akkermansia muciniphila or fragments thereof for treating a metabolic disorder.
Wageningen Universiteit

Bariatric device and weight loss

A bariatric device 10 for use in inducing weight loss, comprising a cardiac element 12, a pyloric element 26, and a connecting element 25 between the two other elements, wherein the connecting element 25 provides structure between the cardiac 12 and pyloric 26 elements, keeping them largely in place and at least intermittently touching and applying pressure to the stomach's cardiac, adjacent fundic and pyloric regions, respectively, which produces a satiety signal to the user, giving the recipient a feeling of fullness and reducing his or her hunger feelings. Alternatively, the cardiac 12 and pyloric 26 elements may be symmetrical, so that the device can orient itself either way in the stomach and still achieve the weight loss function.
Apollo Endosurgery, Inc.

Methods for making conjugates from disulfide-containing proteins

A weight loss device (1, 100) comprising at least one peripheral plate (10, 20, 110, 120) that can be fixed to at least one portion of an upper dental arch (2) or lower dental arch (3) by fixing means, in a fixing configuration. The peripheral plate (10, 20, 110, 120) supports, by way of supporting means (40, 140), at least one central plate (30, 130), which is adapted, in the fixing configuration, to rest against the palate (4) or the floor of the mouth (5) in order to limit the movements of the tongue (7) inside the mouth (6)..

Compounds for the treatment of obesity and methods of use thereof

Pentacyclic triterpene compounds are provided herein. Also provided are pharmaceutical formulations containing a therapeutically effective amount of one or more of the compounds, or pharmaceutically acceptable salts or prodrugs thereof, in combination with one or more pharmaceutically acceptable excipients.
The Children's Medical Center Corporation

Restrictive and/or obstructive implant for inducing weight loss

Described herein is a system for inducing weight loss in a patient, which comprises an extragastric space occupier positionable in contact with an exterior surface of a stomach wall to form an inward protrusion of wall into the stomach, and a retention device positionable in contact with the wall to retain the inward protrusion and to thereby capture the extragastric space occupier within the protrusion.. .
Boston Scientific Scimed, Inc.

Methods and devices for activating brown adipose tissue using electrical energy

Methods and devices are provided for activating brown adipose tissue (bat). Generally, the methods and devices can activate bat to increase thermogenesis, e.g., increase heat production in the patient, which over time can lead to weight loss.
The General Hospital Corporation D/b/a Massachusetts General Hospital

Compositions and methods for inhibition of triglyceride synthesis via synergistic combination of botanical formulations

Compositions and methods for inhibition of triglyceride synthesis via synergistic combination of botanical extracts are described. Specifically, the present invention relates to treating or preventing weight gain or obesity, promoting weight loss, appetite suppression, or the like, as well as managing skin oil production through a synergistic inhibition of diacylglycerol acyltransferase-i (dgat-i) enzyme involved in the triglyceride synthesis and modulation of sterol regulatory element binding protein ic (srebp-ic) and/or peroxisome proliferator activated receptor gamma coactivator i-alpha (pgciα)..
Access Business Group International Llc

Methods and compositions to reduce fat gain, promote weight loss in animals

The present disclosure relates to compositions and related methods to reduce body weight, body fat, waist and hip size, plasma total cholesterol, ldl, triglycerides, blood glucose, leptin and c-reactive protein levels and increase in hdl and serotonin levels in an mammal. The lepticore® formulation disclosed, at both the low and high dosages, is helpful in the management of fat gain and its related complications.

Compounds for the treatment of obesity and methods of use thereof

Pentacyclic triterpene weight loss agents are provided herein. Also provided are pharmaceutical formulations containing a therapeutically effective amount of one or more of the weight loss agents, or pharmaceutically acceptable salts or prodrugs thereof, in combination with one or more pharmaceutically acceptable excipients.
The Massachusetts General Hospital

Devices, methods and uses for removing heat, energy and fluids from a mammal

The present invention provides improved devices for removing energy and fluid from body fluid containing spaces and surfaces of a mammal, and new uses for such devices, including fluid removal, energy removal, increasing metabolic rate; promoting weight loss; preventing esophageal burn-through, reducing beta-amylase accumulation in the brain, delaying or inhibiting the onset of alzheimer's and other senile dementia.. .
Cooltech, Llc

Apparatus and a extracorporeal blood treatment

An apparatus for extracorporeal blood treatment comprises a sensor (10) for emitting a signal indicating a variation in blood volume (Δbv″) of an individual (7) subjected to extracorporeal blood treatment and a sensor (14) for emitting a signal indicating a weight loss of the individual. A control unit (20) receives the signals, compares the ratio between the relative variation of blood volume (Δbv/bv) and the relative variation of weight loss (awl/tw) of the individual with a desired value, and controls the weight loss of the individual on the basis of the comparison.
Gambro Lundia Ab

Tailored rapid interactive mobile messaging (trimm) for weight management

An embodiment in accordance with the present invention provides a system and a method for facilitating a user to meet a self-selected goal. The user enrolls in the program and receives a tailored series of motivational text messages.
The Johns Hopkins University

Micelle sequestering polymers

A polymer composition for sequestering lipid-bile acid micelles in the gastrointestinal (gi) tract is provided. The polymer composition comprises a copolymer of a ph-sensitive monomer and one or more of positively-charged monomers.
University Of Kansas

Method for satiation enhancement of food emulsions using an aerosol delivery system

The method as described herein promotes reduced food calorie intake, for purposes of weight loss or weight maintenance, through use of an aerosol delivery system that increases food emulsion volume (overrun) by as much as 400%, thereby stimulating various satiation feedback mechanisms within the body to effectively gain a net increase in satiation when compared to satiation from calories otherwise ingested without the volume increase produced by said aerosol delivery system.. .

Escalating dosing regimen for effecting weight loss and treating obesity

The present invention is drawn to novel topiramate compositions as well as methods for effecting weight loss, e.g., in the treatment of obesity and related conditions, including conditions associated with and/or caused by obesity per se. The present invention features an escalating dosing regimen adapted for the administration of topiramate and optionally a sympathomimetic agent such as phentermine or bupropion, in the treatment of obesity and related conditions..
Vivus, Inc.

Gastrointestinal implants

A device for inducing weight loss in a patient includes a tubular prosthesis positionable at the gastro-esophageal junction region, preferably below the z-line. In a method for inducing weight loss, the prosthesis is placed such that an opening at its proximal end receives masticated food from the esophagus, and such that the masticated food passes through the pouch and into the stomach via an opening in its distal end..
Boston Scientific Scimed, Inc.

Intermediate strength alloys for high temperature service in liquid-salt cooled energy systems

An alloy consists essentially of, in terms of weight percent: 6 to 8.5 cr, 5.5 to 13.5 mo, 0.4 to 7.5 w, 1 to 2 ti, 0.7 to 0.85 mn, 0.05 to 0.3 al, up to to 0.1 co, 0.08 to 0.5 c, 1 to 5 ta, 1 to 4 nb, 1 to 3 hf, balance ni. The alloy is characterized by, at 850° c., a yield strength of at least 36 ksi, a tensile strength of at least 40 ksi, a creep rupture life at 12 ksi of at least 72.1 hours, and a corrosion rate, expressed in weight loss [g/(cm2sec)]×10−11 during a 1000 hour immersion in liquid flinak at 850° c., in the range of 8 to 25..
Ut-battelle, Llc

Self healing anti corrosive coatings and a process for the preparation thereof

The present invention provides self-healing anti corrosive coatings comprising composites of conducting polymers, chitosan and silica particles along with epoxy useful for corrosion prevention under highly corrosive medium like 3.5% nacl. Tafel plots exhibits significantly high corrosion protection efficiency (99.99%) for the epoxy coatings with 2.0 wt % loading of chitosan-polymer composite.
Council Of Scientific And Industrial Research

Circovirus sequences associated with piglet weight loss disease (pwd)

The genome sequences and the nucleotide sequences coding for the pwd circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a pwd circovirus, also are provided.
Zoetis W Llc

Dietary and nutritional compositions and methods of use

A hydrated lecithin carrier vesicle composition includes lecithin and a triglyceride source or fatty acid in conditioned water. The disclosed compositions may be used for controlling appetite, weight loss, modulating effects from alcohol consumption, and/or delivering active agents to the small intestine..
Brightside Innovations, Inc.

Compositions and methods for weight loss in at risk patient populations

The present disclosure relates to compositions, kits, uses, systems and methods related to naltrexone plus bupropion for treating an overweight or obese subject at increased risk of adverse cardiovascular outcomes. Preferably, the subject has had type-two diabetes for a period of less than 6 years or is a current smoker, optionally that does not have type-two diabetes..
Orexigen Therapeutics, Inc.

Multi-method and multi- treating obesity

A multi-method and multi-apparatus for treating obesity. The multi-method includes a method for estimating a volume of an intragastric balloon appropriate for an individual patient, a method for using an enterocutaneous fistula to inspect an intragastric balloon without sedation and endoscopic complications associated with an upper endoscopy, and a method for decreasing ability of the stomach of an individual patient to distend or expand after a meal increasing satiety and helping the individual patient to comply with a weight loss diet.

Circovirus sequences associated with piglet weight loss disease (pwd)

The genome sequences and the nucleotide sequences coding for the pwd circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a pwd circovirus, also are provided.
Zoetis W Llc

Sorcs1 for use in the treatment of obesity and overweight

The present invention relates to sorcs1-like agents, including sorcs1, nucleic acid molecule encoding expression of sorcs1 and fragments thereof, as well as vectors containing said nucleic acid and to cells expressing sorcs1 and said fragments, for use in a method of reducing appetite, and/or for promoting weight loss, and/or for treating obesity, and/or for increasing metabolism, and/or for increasing thermogenesis, and/or for converting white fat into brown fat. .
Aarhus Universitet

Hepatic protection agent containing eggshell membrane and pharmaceutical composition, food additive and food using the same

The hepatoprotective agent contains eggshell membrane-containing fine powder, wherein the eggshell membrane-containing fine powder is eggshell membrane-containing fine powder having a volume mean particle diameter of 6 μm or less and/or eggshell membrane-containing fine powder having a volume maximum particle diameter of 20 μm or less. When fed with feed including eggshell membrane-containing fine powder with these values (sample c), the liver injury group (ccl4) caused a significant weight loss compared with the control group (control), but the test group esm, the eggshell membrane-fed group (esm) maintained the equal weight to the control group..
Almado Inc.

Methods of administering rifaximin for weight loss and treatment of obesity

Methods of reducing weight in a subject are provided, wherein the methods comprise administering a composition comprising an effective amount of rifaximin to a subject in need of treatment for weight loss. In some embodiments, the subject is considered obese (bmi>30)..
Salix Pharmaceuticals, Ltd

Devices and methods for treating the gastrointestinal system

Devices and methods for less invasively treating the gastrointestinal system, such as the intestinal mucosa of the small bowel. Embodiments described herein may be used to reduce caloric absorption and effectuate weight loss, for example..
Bridgepoint Medical Inc.

Anti-diabetic nutraceutical composition from palm leaf extract

A comestible composition with anti-diabetic property which is effective in lowering the blood glucose and help reduce oxidative stress in diabetics and have anti-diabetic properties that protect against diabetic complications, retarding diabetes related organ degeneration and effective to hinder or prevent ailments or conditions resulting from, or exacerbated by, a chronic increase in blood sugar including: tissue degeneration, cardiovascular disease, kidney degeneration, loss of cognitive function, weight loss, visual impairment, and vasomotor symptoms which contains extract from palm leaf. .
Universiti Putra Malaysia

Kits and methods for sustained weight loss

Disclosed herein are compositions, methods and kits of effecting and prolonging weight loss by administering weight loss agents for treatment phases of predetermined durations.. .
Phytology Labs, Inc.

Methods of treating an overweight or obese subject

The disclosure herein generally relates to methods of treating an overweight or obese condition, and overweight- or obesity-related conditions. In one embodiment, the disclosure provides a method of treating an overweight or obese condition involving administering to the subject in need thereof, an amount of a pharmaceutical composition including metap-2 inhibitory compound, or s salt, ester, or prodrug thereof, effective to result in weight loss in the subject..
Zafgen, Inc.

Anchorable size-varying gastric balloons for weight loss

Provided herein are balloon systems and related methods for the treatment of obesity. The system includes a trans-abdominal gastric cannula and size-varying balloons that, with the assistance of the cannula(s) and anchors, are specially positioned and anchored to the gastric wall.
Ez-off Weightloss, Llc

Pulling rolls for making sheet glass and methods of making and using

A pulling roll for glass manufacture made from a millboard material fired to minimize or eliminate weight loss during operation. Methods for preparing and using such a pulling roll are also disclosed..
Corning Incorporated

Compositions and methods for the treatment of neurological degenerative disorders and neurological diseases

The invention relates to the compounds of formula i or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula i, and methods for the treatment of neurological degenerative disorders and neurological diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection.

Compositions for affecting weight loss

Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (mc3-r) or a melanocortin 4 receptor (mc4-r) compared to normal physiological conditions. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance α-msh activity..
Orexigen Therapeutics, Inc.

Methods for managing weight loss and body mass

The invention provides methods for promoting weight loss by an animal, promoting weight loss by an animal while preventing or minimizing loss of lean body mass by the animal, preventing a reduction in energy metabolism by an animal, reducing the risk of regaining weight by an animal after weight loss, and ameliorating undesirable animal behaviors associated with reduced caloric intake by intermittently feeding an animal a first diet containing calories that meet the animal's maintenance energy requirements and a second diet containing calories that do not meet the animal's maintenance energy requirements. In preferred embodiments, the described feeding pattern and diets are fed in conjunction with one or more weight loss agents..
Nestec Sa

Method of using dietary supplements comprising cinnamon extracts to promote weight loss

A method for promoting weight loss and/or lowering blood glucose comprises an active material which may be cinnamon, an extract of cinnamon, or a derivative of a cinnamon extract. The active material may be utilized in combination with further active ingredients..
In Ingredients, Inc.

Uniaxially stretched multi-layer laminate film, polarizing plate comprising same, optical member for liquid crystal display device, and liquid crystal display device

A uniaxially stretched multi-layer laminate film that exhibits a high polarization performance of 99.5% or more in a simpler configuration than before, a polarizing plate that is composed of the same, an optical member for a liquid crystal display device, and a liquid crystal display device are provided. Namely, in the uniaxially stretched multi-layer laminate film in which a first layer and a second layer are alternately laminated, the uniaxially stretched multi-layer laminate film includes an intermediate layer that has a thickness of 2 μm or more and 30 μm or less; the first layer is composed of a polyester containing a naphthalene dicarboxylic acid ester; the second layer is composed of a copolymer polyester and is an optically isotropic layer that has an average refractive index of 1.50 or more and 1.60 or less; the first layer, the second layer, both first and second layers, or the intermediate layer contains a visible light absorbent, which has a weight loss of less than 10% when it is kept at 300° c.
Teijin Limited

Methods and monitoring and encouraging health and fitness

Methods and apparatus are provided for monitoring and encouraging health and fitness. In accordance with a first aspect, an apparatus is provided that is adapted to assist in weight loss and exercise.

Methods and devices for activating brown adipose tissue with cooling

Methods and devices are provided for activating brown adipose tissue (bat) with cooling. Generally, the methods and devices can activate bat to increase thermogenesis, e.g., increase heat production in the patient, which over time can lead to weight loss and/or improved metabolic function.
Ethicon Endo-surgery, Inc.

System and losing weight

A unique combination of weight loss modalities that produce 20-40 pounds of weigh loss in a six week treatment period. Treatment includes a meal plan chosen to provide adequate protein and nutrition during dieting and to assist metabolism of toxins created from the release of stored fat, high amounts of fiber to assist in collecting toxins and fat in the elimination system and to encourage peristaltic action in the bowel, a bowel toner to further increase peristaltic action in the bowel, stimulating liver functions of fat and toxins.

Methods and treatment with glp-1 receptor agonists

The invention provides methods for treating diabetes or obesity, as well as methods for inducing weight loss, preventing weight gain, or controlling weight in a patient in need thereof. The methods comprise administering to the patient at least one effective dose of a glp-1 receptor agonist, or a regimen of glp-1 receptor agonist comprising a plurality of substantially evenly spaced doses.
Phasebio Pharmaceuticals, Inc.

System and pacing repetitive motion activities

Disclosed is a system and method that allows users to customize audible and visible signals, such as music or video, to maintain a pre-determined or specified pace or to achieve a new pace in repetitive motion activities such as, but not limited to, running, walking, swimming, cycling, aerobics, and the like. Other applications of the system and method include, but are not limited to, enhancing the results of medical rehabilitation programs, physical therapy, weight loss programs, disc jockey services, and industries or manufacturing settings where repetitive motion is common and where audible cues designed to help users maintain a consistent pace are useful.
Pacing Technologies Llc

Compositions containing myristica fragrans

Compositions as nutritional supplements comprising extracts of myristica fragrans for improving exercise performance and for promoting weight loss are disclosed. The compositions may contain, and be standardized to, myristicin and may be administered prior to physical exercise..
Northern Innovations Holding Corp.

Multi-day weight loss kits

The present invention relates generally to weight loss and health management programs in a transportable box, including pre-packaged food items and multi-day meal plans for dieting, losing weight, and promoting health. More specifically, the present invention relates to individual kits for conventional retail outlets for providing a discrete number of prepackaged food items that are to be used in conjunction with grocery supplements, including fresh produce, to provide breakfast, lunch, dinner, snacks, and dessert, over the course of three, five, seven, ten, or twenty-eight days for dieting, eating an age- or gender-specific diet, eating a health-issue specific diet, and/or losing weight..
Nutrisystem Inc.

Glucagon analogues

The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metabolic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods.
Zealand Pharma A/s

Edible coating for plant matter

The present invention discloses composition and methods for reducing the weight loss and/or preserving the natural gloss of post-harvest edible plant matter. In particular, the methods comprising applying to the surface of the plant matter a composition comprising an edible wax having a melting temperature below 70° c.; a hydrocolloid; a fatty acid; an emulsifier; and water, wherein said edible wax is present in a weight percent ranging from about 10% to about 25% of the total weight of the composition..
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.

Methods for weight loss and ketogenic compositions

The present disclosure relates to a weight-loss composition including protein and fat and methods of use. The weight loss composition is substantially free of carbohydrates.
European Ketogenic Weight Loss Clinics Llc

Compositions and methods for treating metabolic disorders

Methods for improving the gastrointestinal tolerability of biguanide compounds and for treating metabolic disorders and/or inducing weight loss in patients in need thereof, particularly in individuals having a contraindication for treatment with biguanide compounds, are provided comprising administering delayed release formulations of such biguanide compounds, including metformin, targeted to the small intestine.. .
Elcelyx Therapeutics, Inc.

Low temperature wearable cooling device for stimulating weight-loss and related methods

Disclosed are several embodiments of wearable cooling devices for applying low temperatures to the human body for the purpose of inducing calorie burn over and above resting metabolic rate, even if the wearer is resting, and for the ultimate purpose of weight loss. It is an objective of this disclosure to describe the wearable cooling devices so that low temperatures are applied comprehensively over regions of the body that will induce significant calorie burn.

Intra-oral device for treating obesity

The present invention relates to an intra-oral device including a carrier that has an outside wall, an inside wall and an occlusal wall connecting the outside wall to the inside wall. The carrier has at least one inset and at least one insert carrying a beneficial agent that is adapted to fit the inset, and the beneficial agent is capable of promoting weight loss.
Dynamic Mouth Devices, L.l.c.

Device and appetite suppression and weight loss management

A device is provided for mounting on a wearer to effect weight loss in the wearer. A central body is connected to a belt for mounting the central body on the abdomen of the wearer and a support structure is provided for stabilizing a position of the central body in relation to the body of the wearer..

Compositions and methods for sustained energy and enhanced weight loss

Disclosed are compositions and methods for sustained energy and enhanced weight loss. A composition for weight loss and sustained energy in a person comprises an effective amount of one or more b vitamins and an effective amount of one or more of lysine, leucine, and methionine.

Compositions and methods for promoting appetite suppression using alkali metals

The present invention relates to a method of suppressing appetite or promoting a stimulant effect in an individual in need thereof, comprising administering to the individual per 24 hour period an effective amount of one or more alkali metals selected from the group consisting of one or more sources of cesium, one or more sources of rubidium, one or more sources of lithium, and combinations thereof. The present invention further relates to weight loss or stimulant compositions comprising one or more alkali metals..
Ashberry International Limited

Creep-resistant, cobalt-free alloys for high temperature, liquid-salt heat exchanger systems

An essentially fe- and co-free alloy is composed essentially of, in terms of weight percent: 6.0 to 7.5 cr, 0 to 0.15 al, 0.5 to 0.85 mn, 11 to 19.5 mo, 0.03 to 4.5 ta, 0.01 to 9 w, 0.03 to 0.08 c, 0 to 1 re, 0 to 1 ru, 0 to 0.001 b, 0.0005 to 0.005 n, balance ni, the alloy being characterized by, at 850° c., a yield strength of at least 25 ksi, a tensile strength of at least 38 ksi, a creep rupture life at 12 ksi of at least 25 hours, and a corrosion rate, expressed in weight loss [g/(cm2 sec)]10−11 during a 1000 hour immersion in liquid flinak at 850° c., in the range of 3 to 10.. .
Ut-battelle, Llc

Gastric space occupier systems and methods of use

Systems for controlling obesity utilize a number of space occupiers positioned in the stomach to reduce the effective volume of the stomach. Such arrangements provides sufficient stomach volume consumption to induce weight loss, but enable use of space occupiers that are proportioned to minimize the threat of obstruction even if they should migrate into the intestine.
Boston Scientific Scimed, Inc

Pharmaceutical composition for preventing and treating chronic obstructive pulmonary diseases, containing phyllostachys nigra munro var henosis stapf extract as active ingredient

The present invention relates to a method for treating chronic obstructive pulmonary disease (copd) comprising the step of administering the extract of phyllostachys nigra munro var. Henosis stapf as an active ingredient.
University-industry Cooperation Group Of Kyung Hee University

Anti-activin a antibodies and uses thereof

The present invention provides antibodies that bind to activin a and methods of using the same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to activin a with high affinity.
Regeneron Pharmaceuticals, Inc.

Creep-resistant, cobalt-containing alloys for high temperature, liquid-salt heat exchanger systems

An essentially fe-free alloy consists essentially of, in terms of weight percent: 4 to 11 co, 6.5 to 7.5 cr, 0 to 0.15 al, 0.5 to 0.85 mn, 11 to 20 mo, 1 to 3.5 ta, 0.05 to 9 w, 0.03 to 0.08 c, 0 to 0.001 b, 0.0005 to 0.005 n, balance ni, the alloy being characterized by, at 850° c., a yield strength of at least 25 ksi, a tensile strength of at least 45 ksi, a creep rupture life at 12 ksi of at least 10 hours, and a corrosion rate, expressed in weight loss [g(cm2sec)]10−11 during a 1000 hour immersion in liquid flinak at 850° c., in the range of 5 to 20.. .
Ut- Battelle, Llc

Compositions and methods for preventing and treating mucositis and weight loss

Pharmaceutical compositions comprising 5-[2-pyrazinyl]-4-methyl-1,2-3-thione or an analogue, derivative, metabolite, prodrug, solvate or a pharmaceutically acceptable salt thereof; and a pharmaceutical carrier, which promotes association with the outer wall of a subject's digestive tract are described as well as their uses in treating and preventing mucositis and cachexia.. .
St Ip Holding Ag

Devices and methods for weight control and weight loss

The present invention provides, compositions, devices; and methods for affecting, among other things, weight loss and/or weight control, by sequestering nutrients or other compounds such as toxins from absorption in the digestive tract. The compositions, devices, and methods employ one or more members made of a compressible, absorbent matrix material.
Primigenia, Llc

Pharmaceutical compositions for combination therapy

This invention relates to the use of pharmaceutical compositions comprising a therapeutically effective combination of tesofensine and metoprolol for preventing the cardiovascular side effects of tesofensine, while leaving the robust inhibitory efficacy on food intake and body weight loss unaffected.. .
Neurosearch A/s

Combination of a monosubstituted sulfamate derivate of the natural monosaccharide d-fructose (topiramate) with an anti-depressant from the phenyl ketone class (bupropion) for treating obesity and plurimetabolic syndromes

Combination of a monosubstituted sulfamate derivate of the natural monosaccharide d-fructose (topiramate) with an anti-depressant from the phenyl ketone class (bupropion) for treating obesity and plurimetabolic syndromes, which takes into consideration “combined therapy”, using two drugs (topiramate and bupropion) with different action mechanisms, with the intent of promoting a synergistic effect on weight loss. The solid pharmaceutical form contains from 75 to 400 mg of bupropion chlorohydrate combined with 25 to 200 mg of topiramate; the presential are added in the formulation until q.s.p 1 pill/coated pill..
Vencio & Stival Medicos Associados S/s Ltda (epp)

Method for weight loss and management and herbal composition for achieving the same

A natural formulation and associated method promotes fat and weight loss while decreasing food cravings, boosting metabolic rate, and supporting the immune system. An instant coffee blend is provided to aid in the delivery of such a composition.

Escalating dosing regimen for effecting weight loss and treating obesity

The present invention is drawn to novel topiramate compositions as well as methods for effecting weight loss, e.g., in the treatment of obesity and related conditions, including conditions associated with and/or caused by obesity per se. The present invention features an escalating dosing regimen adapted for the administration of topiramate and optionally a sympathomimetic agent such as phentermine or bupropion, in the treatment of obesity and related conditions..
Vivus, Inc.

Low dose topiramate/phentermine composition and methods of use thereof

A method for effecting weight loss by administering a combination of topiramate and phentermine is provided. The phentermine is generally administered in immediate release form, in a daily dose in the range of 2 mg to 8 mg, in combination with a daily dose of topiramate selected to prevent the loss of effectiveness of phentermine alone.
Vivus, Inc.

Intestinal devices and methods for facilitating weight loss

Intestinal devices and methods for facilitating weight loss. In at least one embodiment of a method of patient treatment of the present disclosure, the method comprises the step of positioning a device, that is configured to reduce or limit localized intestinal distension, around a portion of an intestine of a patient..

Estrogen receptor modulators for reducing body weight

The present invention relates to a method of reducing the body weight of a subject by administering an effective amount of an estrogen receptor modulator (erm), optionally, in combination with an anti-obesity or weight loss agent.. .
Rosscreening, Inc.



Weight Loss topics:
  • Weight Loss
  • Lithium Carbonate
  • Nutritional Supplement
  • Overweight
  • Electrolyte
  • Gastrostomy
  • Supplements
  • Body Weight
  • Forskohlii
  • Nutritional Formula
  • Body Mass Index
  • Weight Management
  • Radio Frequency Identification
  • Metabolism
  • Digestive Tract


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Weight Loss for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Weight Loss with additional patents listed. Browse our RSS directory or Search for other possible listings.


    3.0656

    file did exist - file did put11719

    3 - 1 - 246